JP2005511619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511619A5 JP2005511619A5 JP2003543612A JP2003543612A JP2005511619A5 JP 2005511619 A5 JP2005511619 A5 JP 2005511619A5 JP 2003543612 A JP2003543612 A JP 2003543612A JP 2003543612 A JP2003543612 A JP 2003543612A JP 2005511619 A5 JP2005511619 A5 JP 2005511619A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- treatment
- active ingredient
- heart disease
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10156249A DE10156249A1 (de) | 2001-11-15 | 2001-11-15 | Regulation der cGMP-spezifischen Phosphodiesterase 9A |
| PCT/EP2002/012550 WO2003041725A2 (de) | 2001-11-15 | 2002-11-11 | REGULATION DER cGMP-SPEZIFISCHEN PHOSPHODIESTERASE 9A |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005511619A JP2005511619A (ja) | 2005-04-28 |
| JP2005511619A5 true JP2005511619A5 (https=) | 2006-01-05 |
Family
ID=7705937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003543612A Withdrawn JP2005511619A (ja) | 2001-11-15 | 2002-11-11 | ｃＧＭＰ−特異的ホスホジエステラーゼ９Ａの調節 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040266736A1 (https=) |
| EP (1) | EP1448210A2 (https=) |
| JP (1) | JP2005511619A (https=) |
| AU (1) | AU2002337186A1 (https=) |
| DE (1) | DE10156249A1 (https=) |
| WO (1) | WO2003041725A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10320785A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
| US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
| DE10328479A1 (de) * | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
| DE102004001873A1 (de) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
| WO2006061994A1 (ja) * | 2004-12-08 | 2006-06-15 | Takeshi Yamamoto | 遺伝子配列検査法 |
| DE102005024494A1 (de) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| KR20110063447A (ko) | 2008-09-08 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도 |
| PT2414363E (pt) | 2009-03-31 | 2014-02-26 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a |
| TW201118099A (en) * | 2009-08-12 | 2011-06-01 | Boehringer Ingelheim Int | New compounds for the treatment of CNS disorders |
| EP2603511B1 (en) | 2010-08-12 | 2017-03-15 | Boehringer Ingelheim International GmbH | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| WO2020182076A1 (zh) * | 2019-03-08 | 2020-09-17 | 南京药捷安康生物科技有限公司 | 磷酸二酯酶抑制剂的用途 |
| CN120329388B (zh) * | 2025-04-30 | 2025-09-26 | 中日友好医院(中日友好临床医学研究所) | 一种双靶点多肽及其在心衰治疗中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4211239C2 (de) * | 1992-04-03 | 1995-11-16 | Max Planck Gesellschaft | Arzneimittel gegen Herz-Kreislauf-Erkrankungen |
| US5922595A (en) * | 1997-12-09 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Cyclic GMP phosphodiesterase |
-
2001
- 2001-11-15 DE DE10156249A patent/DE10156249A1/de not_active Withdrawn
-
2002
- 2002-11-11 US US10/495,638 patent/US20040266736A1/en not_active Abandoned
- 2002-11-11 AU AU2002337186A patent/AU2002337186A1/en not_active Abandoned
- 2002-11-11 JP JP2003543612A patent/JP2005511619A/ja not_active Withdrawn
- 2002-11-11 EP EP02772410A patent/EP1448210A2/de not_active Withdrawn
- 2002-11-11 WO PCT/EP2002/012550 patent/WO2003041725A2/de not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511619A5 (https=) | ||
| NO2025027I1 (no) | Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget. | |
| CA2106172A1 (en) | Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention | |
| ATE265857T1 (de) | Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie | |
| ME02688B (me) | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta | |
| HUP0401963A3 (en) | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | |
| MX2009003921A (es) | Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b. | |
| IT1318649B1 (it) | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti. | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| JP2006514116A5 (https=) | ||
| JP2005509503A5 (https=) | ||
| EE200300328A (et) | IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks | |
| JP2005505605A5 (https=) | ||
| MY130445A (en) | Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone | |
| CA2457982A1 (en) | Use of nefiracetam for treating neurodegeneration | |
| PT1534296E (pt) | UTILIZAÇÃO DE CILOBRADINA OU DOS SEUS SAIS FARMACEUTICAMENTE ACEITÁVEIS PARA O TRATAMENTO OU PREVENÇÃO DA INSUFICIjNCIA CARDÍACA | |
| DE60322871D1 (de) | Thaltende zubereitungen | |
| NO20041878L (no) | Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel. | |
| JP2004530642A5 (https=) | ||
| WO2005025545A3 (en) | Pharmaceutical formulation for controlled release of selodenoson | |
| JP2004059440A5 (https=) | ||
| TH48054A3 (th) | วิธีการรักษาอาธีโรสเคลอโรซิส โดยใช้ตัวยับยั้ง aP2 และสิ่งผสมรวม | |
| RU2002103738A (ru) | Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний | |
| RU2000122597A (ru) | Лекарственное средство Витал-I для лечения острых респираторных заболеваний | |
| SE9902674D0 (sv) | New composition |